相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro
Lilian Amrein et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice
Ningfei An et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
FLT3 signals via the adapter protein Grb10 and overexpression of Grb10 leads to aberrant cell proliferation in acute myeloid leukemia
Julhash U. Kazi et al.
MOLECULAR ONCOLOGY (2013)
Role of PRAS40 in Akt and mTOR signaling in health and disease
Claudia Wiza et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2012)
PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances
Lomon So et al.
BIOCHEMICAL JOURNAL (2012)
PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma
Sarah A. Meadows et al.
BLOOD (2012)
The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia
Roel Polak et al.
BLOOD (2012)
Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007
Graca M. Dores et al.
BLOOD (2012)
Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment
Zhihong Zeng et al.
BLOOD (2012)
Clinical and Proteomic Characterization of Acute Myeloid Leukemia With Mutated RAS
Tapan M. Kadia et al.
CANCER (2012)
Targeting the Insulin-like Growth Factor Axis for the Development of Novel Therapeutics in Oncology
Jin Gao et al.
CANCER RESEARCH (2012)
Temporal Changes in PTEN and mTORC2 Regulation of Hematopoietic Stem Cell Self-Renewal and Leukemia Suppression
Jeffrey A. Magee et al.
CELL STEM CELL (2012)
The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Non-small-Cell Lung Cancer
Assunta Sgambato et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Selective small molecule inhibitors of p110α and δ isoforms of phosphoinosityl-3-kinase are cytotoxic to human acute myeloid leukemia progenitors
Yan Xing et al.
EXPERIMENTAL HEMATOLOGY (2012)
Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for vertical and lateral combination strategies
Maria Rosaria Ricciardi et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2012)
Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett et al.
NATURE (2012)
Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
Alex Kentsis et al.
NATURE MEDICINE (2012)
Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155
D. W. Lee et al.
ONCOGENE (2012)
PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies
Lise Willems et al.
CURRENT ONCOLOGY REPORTS (2012)
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment
Alberto M. Martelli et al.
ONCOTARGET (2012)
Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.
James A. McCubrey et al.
ONCOTARGET (2012)
CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
Brian J. Lannutti et al.
BLOOD (2011)
Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition
Carmen Blanco-Aparicio et al.
CANCER LETTERS (2011)
Activation of mTORC2 by Association with the Ribosome
Vittoria Zinzalla et al.
CELL (2011)
Phosphatidylinositol 3-kinase-C2β Inhibits Cisplatin-mediated Apoptosis via the Akt Pathway in Oesophageal Squamous Cell Carcinoma
Z. Liu et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2011)
Gene expression profiling in MDS and AML: potential and future avenues
K. Theilgaard-Monch et al.
LEUKEMIA (2011)
Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway
A. M. Martelli et al.
LEUKEMIA (2011)
The cancer stem cell: premises, promises and challenges
Hans Clevers
NATURE MEDICINE (2011)
Stem cell gene expression programs influence clinical outcome in human leukemia
Kolja Eppert et al.
NATURE MEDICINE (2011)
PI3Kδ Inhibitors in Cancer: Rationale and Serendipity Merge in the Clinic
David A. Fruman et al.
CANCER DISCOVERY (2011)
Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice
Michael G. Kharas et al.
BLOOD (2010)
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
Sarah E. M. Herman et al.
BLOOD (2010)
Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia
Nicolas Chapuis et al.
CLINICAL CANCER RESEARCH (2010)
Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39
Dexin Kong et al.
EUROPEAN JOURNAL OF CANCER (2010)
Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody
Nicolas Chapuis et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers
Laurent Brault et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Akt and PKC are involved not only in upregulation of telomerase activity but also in cell differentiation-related function via mTORC2 in leukemia cells
Osamu Yamada et al.
HISTOCHEMISTRY AND CELL BIOLOGY (2010)
RUNX1 Repression-Independent Mechanisms of Leukemogenesis by Fusion Genes CBFB-MYH11 and AML1-ETO (RUNX1-RUNX1T1)
R. Katherine Hyde et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2010)
mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells
Weina Chen et al.
MOLECULAR CANCER (2010)
Phosphoinositide signalling in cancer: beyond PI3K and PTEN
Tom D. Bunney et al.
NATURE REVIEWS CANCER (2010)
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
Zhihong Zeng et al.
BLOOD (2009)
Expression of Insulin Receptor Isoform A and Insulin-like Growth Factor-1 Receptor in Human Acute Myelogenous Leukemia: Effect of the Dual-Receptor Inhibitor BMS-536924 In vitro
Andrea E. Wahner Hendrickson et al.
CANCER RESEARCH (2009)
Inhibition of Class I Phosphoinositide 3-Kinase Activity Impairs Proliferation and Triggers Apoptosis in Acute Promyelocytic Leukemia without Affecting Atra-Induced Differentiation
Clotilde Billottet et al.
CANCER RESEARCH (2009)
Targeting translation in acute myeloid leukemia A new paradigm for therapy?
Jerome Tamburini et al.
CELL CYCLE (2009)
PI3K/mTORC1 activation in hamartoma syndromes Therapeutic prospects
Vera P. Krymskaya et al.
CELL CYCLE (2009)
Mammalian target of rapamycin complex 1-mediated phosphorylation of eukaryotic initiation factor 4E-binding protein 1 requires multiple protein-protein interactions for substrate recognition
Elaine A. Dunlop et al.
CELLULAR SIGNALLING (2009)
Akt-dependent and -independent mechanisms of mTOR regulation in cancer
Regan M. Memmott et al.
CELLULAR SIGNALLING (2009)
Specific Activation of mTORC1 by Rheb G-protein in Vitro Involves Enhanced Recruitment of Its Substrate Protein
Tatsuhiro Sato et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
Florence I. Raynaud et al.
MOLECULAR CANCER THERAPEUTICS (2009)
The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia
N. Gallay et al.
LEUKEMIA (2009)
Molecular mechanisms of mTOR-mediated translational control
Xiaoju Max Ma et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2009)
p210Bcr-Abl desensitizes Cdc42 GTPase signaling for SDF-1α-directed migration in chronic myeloid leukemia cells
Y-C Chang et al.
ONCOGENE (2009)
A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN
Meghdad Rahdar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
NATURE REVIEWS CANCER (2009)
The regulation and function of Class III PI3Ks: novel roles for Vps34
Jonathan M. Backer
BIOCHEMICAL JOURNAL (2008)
Translating an Antagonist of Chemokine Receptor CXCR4: From Bench to Bedside
Donald Wong et al.
CLINICAL CANCER RESEARCH (2008)
The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance
Mark B. Meads et al.
CLINICAL CANCER RESEARCH (2008)
PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability
Ana Silva et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species
Chong Chen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer
Adrian J. Folkes et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2008)
The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML
K. Kojima et al.
LEUKEMIA (2008)
PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML
S. Park et al.
LEUKEMIA (2008)
Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis
E. K. Thomas et al.
LEUKEMIA (2008)
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
Richard F. Schlenk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells
S. Horn et al.
ONCOGENE (2008)
Drug discovery approaches targeting the PI3K/Akt pathway in cancer
C. Garcia-Echeverria et al.
ONCOGENE (2008)
Prognostic relevance of FLT3-TKD mutations in AML:: the combination matters -: an analysis of 3082 patients
Ulrike Bacher et al.
BLOOD (2008)
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways
Jerome Tamburini et al.
BLOOD (2008)
Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110α inhibitors
Masahiko Hayakawa et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2007)
Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway
K. T. Doepfner et al.
LEUKEMIA (2007)
Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients
Jerome Tamburini et al.
BLOOD (2007)
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases
Florence I. Raynaud et al.
CANCER RESEARCH (2007)
Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype
Sergej Konoplev et al.
CANCER (2007)
Protein kinase CK2α as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia
Jin Seok Kim et al.
CLINICAL CANCER RESEARCH (2007)
Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts
P. L. Tazzari et al.
LEUKEMIA (2007)
Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene
Claudia I. Mueller et al.
LEUKEMIA RESEARCH (2007)
Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival
Shahab Uddin et al.
BLOOD (2006)
Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias
Zhihong Zeng et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Stem cell c-KIT and HOXB4 genes:: Critical roles and mechanisms in self-renewal, proliferation, and differentiation
Shilpa Sharma et al.
STEM CELLS AND DEVELOPMENT (2006)
A selective inhibitor of the p110δ isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16
C. Billottet et al.
ONCOGENE (2006)
Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia
Steven M. Kornblau et al.
BLOOD (2006)
IGF-I mediated survival pathways in normal and malignant cells
Raushan T. Kurmasheva et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2006)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells
Omer H. Yilmaz et al.
NATURE (2006)
PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention
Jiwang Zhang et al.
NATURE (2006)
A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling
Zachary A. Knight et al.
CELL (2006)
Implications of NRAS mutations in AML:: a study of 2502 patients
Ulrike Bacher et al.
BLOOD (2006)
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Qi-Wen Fan et al.
CANCER CELL (2006)
Prognostic impact of c-KIT mutations in core binding factor leukemas:: an Italian retrospective study
R Cairoli et al.
BLOOD (2006)
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
M Cully et al.
NATURE REVIEWS CANCER (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Constitutive phosphoinositide 3-kinase activation in acute myeloid leukemia is not due to p110δ mutations
P Cornillet-Lefebvre et al.
LEUKEMIA (2006)
A pharmacological map of the PI3-K family defines a role for p110 alpha in insulin signaling
Zachary A. Knight et al.
CELL (2006)
Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice
O Kosmider et al.
CANCER CELL (2005)
Assessment of somatic mutations in phosphatidylinositol 3-kinase gene in human lymphoma and acute leukaemia
M Bousquet et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myelold transformation
CH Brandts et al.
CANCER RESEARCH (2005)
Genetics of myeloid malignancies:: Pathogenetic and clinical implications
S Fröhling et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia
P Sujobert et al.
BLOOD (2005)
Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22)
T Nanri et al.
LEUKEMIA (2005)
FLT-3: a new focus in the understanding of acute leukemia
A Markovic et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2005)
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
DD Sarbassov et al.
SCIENCE (2005)
The treatment of AML: Current status and novel approaches
AK Burnett
HEMATOLOGY (2005)
High frequency of mutations of the PIK3CA gene in human cancers
Y Samuels et al.
SCIENCE (2004)
A novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin
GJ Browne et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias
S Zhao et al.
LEUKEMIA (2004)
Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold
ZA Knight et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2004)
A sustained activation of PI3K/NF-κB pathway is critical for the survival of chronic lymphocytic leukemia B cells
S Cuní et al.
LEUKEMIA (2004)
The biology and clinical relevance of the PTEN tumor suppressor pathway
I Sansal et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Advances in protein kinase B signalling:: AKTion on multiple fronts
DP Brazil et al.
TRENDS IN BIOCHEMICAL SCIENCES (2004)
Lysophospholipids synergistically promote primitive hematopoietic cell chemotaxis via a mechanism involving Vav 1
AD Whetton et al.
BLOOD (2003)
Phosphatase and tensin homologue phosphorylation in the C-terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome
JW Cheong et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Survival of acute myeloid leukemia cells requires PI3 kinase activation
Q Xu et al.
BLOOD (2003)
Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias
RS Care et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable
YH Min et al.
LEUKEMIA (2003)
Essential role of phosphoinositide 3-kinase δ in neutrophil directional movement
C Sadhu et al.
JOURNAL OF IMMUNOLOGY (2003)
Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia
JM Luo et al.
LEUKEMIA (2003)
Transgenic expression of stromal cell-derived factor-1/CXC chemokine ligand 12 enhances myeloid progenitor cell survival/antiapoptosis in vitro in response to growth factor withdrawal and enhances myelopoiesis in vivo
HE Broxmeyer et al.
JOURNAL OF IMMUNOLOGY (2003)
Two distinct phosphoinositide 3-kinases mediate polypeptide growth factor-stimulated PKB activation
A Arcaro et al.
EMBO JOURNAL (2002)
Phosphatidylinositol (3,4,5)P3 is essential but not sufficient for protein kinase B (PKB) activation; phosphatidylinositol (3,4)P2 is required for PKB phosphorylation at Ser-473 -: Studies using cells from SH2-containing inositol-5-phosphatase knockout mice
MP Scheid et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
A phosphatase associated with metastasis of colorectal cancer
S Saha et al.
SCIENCE (2001)
The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus - Implications for PTEN stability to proteasome-mediated degradation
J Torres et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Mutational analysis of the tumour suppressor gene MMAC1/PTEN in malignant myeloid disorders
A Aggerholm et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2000)
Phosphorylation of the PTEN tail regulates protein stability and function
F Vazquez et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals
DM O'Gorman et al.
LEUKEMIA (2000)
Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia
R Mohle et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
分享论文
